Skip to main content

Advertisement

SpringerLink
Log in

Characterization of Interleukin-33 and Soluble ST2 in Serum and Their Association with Disease Severity in Patients with Chronic Kidney Disease

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Introduction

This study aims to test the serum levels of interleukin-33 (IL-33) and soluble ST2 (sST2) in patients with chronic kidney disease (CKD) and to evaluate their association with disease severity.

Methods

Sixty-nine patients with CKD were enrolled, disease severity was assessed, and clinical data were collected. Twelve healthy volunteers served as healthy individuals. Serum IL-33 and sST2 were tested by enzyme-linked immunosorbent assay.

Results

The patients were classified into five categories based on their estimated glomerular filtration rate (eGFR). No difference was found as to the serum concentration of IL-33 between CKD patients and healthy individuals (p = 0.656), while a higher serum level of sST2 was found in CKD patients (p = 0.003). The correlation analysis revealed a significant correlation between the serum level of sST2 and disease severity (r = 0.586; p < 0.001). A higher level of sST2 was found in CKD patients with elevated parathyroid hormone (p = 0.001). Serum sST2 correlated with parathyroid hormone (r = 0.412; p < 0.001), serum phosphorus (r = 0.545; p < 0.001), and serum calcium (r = −0.494; p < 0.001).

Conclusion

An elevated concentration of serum sST2 is found in CKD patients and correlates with disease severity. Serum sST2 may be also associated with parathyroid hormone disorder of CKD. The sST2 may have an important role in the development of CKD or as a marker of disease severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.

    PubMed  CAS  Google Scholar 

  2. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95:6930–5.

    Article  PubMed  CAS  Google Scholar 

  3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.

    Article  PubMed  CAS  Google Scholar 

  4. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–40.

    Article  PubMed  CAS  Google Scholar 

  5. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282–7.

    Article  PubMed  CAS  Google Scholar 

  6. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738–49.

    Article  PubMed  CAS  Google Scholar 

  7. Pushparaj PN, Tay HK, H’ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773–8.

    Article  PubMed  CAS  Google Scholar 

  8. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.

    Article  PubMed  CAS  Google Scholar 

  9. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. PNAS. 2010;4:8017–22.

    Article  Google Scholar 

  10. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology. 2010;49:520–7.

    Article  PubMed  CAS  Google Scholar 

  11. Hung AM, Crawford DC, Griffin MR, Brown-Gentry K, Lipkowitz MS, Siew ED, Cavanaugh K, Lewis JB, Ikizler TA. CRP polymorphisms and progression of chronic kidney disease in African Americans. Clin J Am Soc Nephrol. 2010;5:24–33.

    Article  PubMed  CAS  Google Scholar 

  12. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68:237–45.

    Article  PubMed  CAS  Google Scholar 

  13. Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ, Hsieh BS. Plasma interleukin-18 levels in chronic renal failure and continuous ambulatory peritoneal dialysis. Blood Purif. 2005;23:144–8.

    Article  PubMed  CAS  Google Scholar 

  14. Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118:83–91.

    Article  PubMed  CAS  Google Scholar 

  15. Sester U, Sester M, Hauk M, Kaul H, Kohler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant. 2000;15:1217–23.

    Article  PubMed  CAS  Google Scholar 

  16. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis. 2001;38:286–95.

    Article  PubMed  CAS  Google Scholar 

  17. Torres VE. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis. 2010;17:190–204.

    Article  PubMed  Google Scholar 

  18. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526–33.

    Article  PubMed  Google Scholar 

  19. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33–43.

    Article  PubMed  CAS  Google Scholar 

  20. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, Gillespie MT, Quinn JM. Interleukin-33, a target of parathyroid hormone and oncostatin M, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152:1911–22.

    Article  PubMed  CAS  Google Scholar 

  21. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory board: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am. J. Kidney Dis. 2002;39:S1–246.

    Google Scholar 

  22. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease: how can we treat it. Blood Purif. 2008;26:291–9.

    Article  PubMed  CAS  Google Scholar 

  23. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E, Spittler A, Sautner T, Bonaros N, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004;30:1468–73.

    Article  PubMed  Google Scholar 

  24. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–90.

    Article  PubMed  CAS  Google Scholar 

  25. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality inpatients with acute destabilized heart failure. Clin Chem. 2008;54:752–6.

    Article  PubMed  CAS  Google Scholar 

  26. Bruneau S, Le Berre L, Herve C, Valanciute A, Kamal M, Naulet J, Tesson L, Foucher Y, Soulillou JP, Sahali D, Dantal J. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am J Kidney Dis. 2009;54:522–32.

    Article  PubMed  CAS  Google Scholar 

  27. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369–80.

    Article  PubMed  CAS  Google Scholar 

  28. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105:10913–8.

    Article  PubMed  CAS  Google Scholar 

  29. Dinarello CA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity. 2005;23:461–2.

    Article  PubMed  CAS  Google Scholar 

  30. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882–9.

    Article  PubMed  CAS  Google Scholar 

  31. Medici D, Razzaque MS, Deluca S, Rector TL, Hou B, Kang K, Goetz R, Mohammadi M, Kuro-O M, Olsen BR, Lanske B. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D induced apoptosis. J Cell Biol. 2008;182:459–65.

    Article  PubMed  CAS  Google Scholar 

  32. Raggatt LJ, Qin L, Tamasi J, Jefcoat Jr SC, Shimizu E, Selvamurugan N, Liew FY, Bevelock L, Feyen JH, Partridge NC. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem. 2008;283:6790–8.

    Article  PubMed  CAS  Google Scholar 

  33. Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B, Reilly J, Kerr S, Millar NL, Kamradt T, McInnes IB, Fallon PG, David JP, Liew FY, Schett G. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-a-mediated bone loss. J Immunol. 2011;186:6097–105.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The present work was supported by a research grant from The First Affiliated Hospital of Harbin Medical University (2009B27) and Heilongjiang Provincial Health Bureau (2009-062). We appreciate the support provided by all colleagues in the study department.

Disclosure

All the authors declared no competing interests.

Author information

Authors and Affiliations

  1. Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, No. 23 Youzheng Street, Harbin, China

    Yu-Shi Bao, Shi-Ping Na, Xi-Bei Jia, Rui-Chan Liu, Cheng-Yuan Yu, Su-Hong Mu & Ru-Juan Xie

  2. Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, China

    Ping Zhang

Authors
  1. Yu-Shi Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shi-Ping Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xi-Bei Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui-Chan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cheng-Yuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Su-Hong Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ru-Juan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ru-Juan Xie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bao, YS., Na, SP., Zhang, P. et al. Characterization of Interleukin-33 and Soluble ST2 in Serum and Their Association with Disease Severity in Patients with Chronic Kidney Disease. J Clin Immunol 32, 587–594 (2012). https://doi.org/10.1007/s10875-011-9622-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-011-9622-7

Keywords

Search

Navigation